1. Home
  2. PEN vs CYTK Comparison

PEN vs CYTK Comparison

Compare PEN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Penumbra Inc.

PEN

Penumbra Inc.

HOLD

Current Price

$319.34

Market Cap

12.8B

Sector

Health Care

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$69.38

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEN
CYTK
Founded
2004
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8B
10.4B
IPO Year
2015
2004

Fundamental Metrics

Financial Performance
Metric
PEN
CYTK
Price
$319.34
$69.38
Analyst Decision
Hold
Strong Buy
Analyst Count
16
19
Target Price
$360.14
$89.26
AVG Volume (30 Days)
379.6K
1.7M
Earning Date
05-12-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
1155.56
N/A
EPS
0.82
N/A
Revenue
$1,403,665,000.00
$13,368,000.00
Revenue This Year
$14.34
$7.37
Revenue Next Year
$13.71
$310.19
P/E Ratio
$389.44
N/A
Revenue Growth
17.50
N/A
52 Week Low
$221.26
$31.99
52 Week High
$362.41
$80.20

Technical Indicators

Market Signals
Indicator
PEN
CYTK
Relative Strength Index (RSI) 38.05 45.21
Support Level $317.81 $59.07
Resistance Level $322.24 $70.69
Average True Range (ATR) 2.48 2.87
MACD 0.04 -1.15
Stochastic Oscillator 14.25 25.26

Price Performance

Historical Comparison
PEN
CYTK

About PEN Penumbra Inc.

Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: